688029 南微医学
已收盘 04-30 15:00:00
资讯
新帖
简况
南微医学获得发明专利授权：“一种压力泵控制方法”
证券之星 · 05-01 02:40
南微医学获得发明专利授权：“一种压力泵控制方法”
【机构调研记录】财通基金调研温氏股份、南微医学等13只个股（附名单）
证券之星 · 04-30 08:04
【机构调研记录】财通基金调研温氏股份、南微医学等13只个股（附名单）
【机构调研记录】红土创新基金调研南微医学、传音控股等4只个股（附名单）
证券之星 · 04-30 08:04
【机构调研记录】红土创新基金调研南微医学、传音控股等4只个股（附名单）
【机构调研记录】国新国证基金调研南微医学、云涌科技等3只个股（附名单）
证券之星 · 04-30 08:03
【机构调研记录】国新国证基金调研南微医学、云涌科技等3只个股（附名单）
【机构调研记录】先锋基金调研温氏股份、南微医学等4只个股（附名单）
证券之星 · 04-30 08:02
【机构调研记录】先锋基金调研温氏股份、南微医学等4只个股（附名单）
【机构调研记录】中庚基金调研华明装备、南微医学等6只个股（附名单）
证券之星 · 04-30 08:01
【机构调研记录】中庚基金调研华明装备、南微医学等6只个股（附名单）
【私募调研记录】汐泰投资调研南微医学、海油发展等3只个股（附名单）
证券之星 · 04-30 08:00
【私募调研记录】汐泰投资调研南微医学、海油发展等3只个股（附名单）
南微医学：公司预计，欧盟相关调查及国内集采不会对今年业绩造成较大影响
证券之星 · 04-29 19:03
南微医学：公司预计，欧盟相关调查及国内集采不会对今年业绩造成较大影响
南微医学04月29日遭主力抛售2476万元 环比增加120.48%
自选股智能写手 · 04-29 15:19
南微医学04月29日遭主力抛售2476万元 环比增加120.48%
南微医学(688029)：利润超预期 规模扩张转为价值增长
国泰君安证券股... · 04-28
南微医学(688029)：利润超预期 规模扩张转为价值增长
南微医学(688029)：2023年业绩符合预期 海外业务加速成长
中金公司 · 04-27
南微医学(688029)：2023年业绩符合预期 海外业务加速成长
南微医学(688029)：国内稳步增长 海外高增持续
浙商证券股份有... · 04-27
南微医学(688029)：国内稳步增长 海外高增持续
南微医学(688029)：23年业绩符合预期 公司持续加深海外渠道建设
广发证券股份有... · 04-26
南微医学(688029)：23年业绩符合预期 公司持续加深海外渠道建设
南微医学(688029)3月31日股东户数1.04万户，较上期增加29.3%
证券之星 · 04-26
南微医学(688029)3月31日股东户数1.04万户，较上期增加29.3%
东吴证券：给予南微医学买入评级
证券之星 · 04-26
东吴证券：给予南微医学买入评级
东吴证券给予南微医学买入评级，2023年年报及2024年一季报点评：业绩符合预期，海外市场逐步打开
每日经济新闻 · 04-26
东吴证券给予南微医学买入评级，2023年年报及2024年一季报点评：业绩符合预期，海外市场逐步打开
南微医学2023年营收24.11亿净利4.86亿 董事长隆晓辉薪酬487万
挖贝网 · 04-26
南微医学2023年营收24.11亿净利4.86亿 董事长隆晓辉薪酬487万
南微医学(688029)：海外收入快速增长 盈利持续改善
华泰证券 · 04-26
南微医学(688029)：海外收入快速增长 盈利持续改善
图解南微医学一季报：第一季度单季净利润同比增41.36%
证券之星 · 04-26
图解南微医学一季报：第一季度单季净利润同比增41.36%
图解南微医学年报：第四季度单季净利润同比减4.09%
证券之星 · 04-26
图解南微医学年报：第四季度单季净利润同比减4.09%
公司概况
公司名称：
南微医学科技股份有限公司
所属行业：
专用设备制造业
上市日期：
2019-07-22
主营业务：
南微医学科技股份有限公司的主营业务为微创医疗器械的研发、制造和销售。公司主要产品包括内镜诊疗器械、微波消融设备及耗材、一次性内镜。公司内镜诊疗器械主要包括活检类、止血和闭合类、EMR/ESD 类、扩张类、ERCP 类、EUS/EBUS类等六大类60多种上百个规格系列产品，微波消融主要包括微波消融仪和微波消融针系列产品。公司是我国内镜诊疗器械的主要制造商之一，是国内内镜诊疗器械、耗材细分领域中起步较早、创新能力强、产品线丰富、规模优势明显、迈向国际化的行业龙头企业。
发行价格：
52.45
{"stockData":{"symbol":"688029","market":"SH","secType":"STK","nameCN":"南微医学","latestPrice":72.66,"timestamp":1714460400000,"preClose":72.78,"halted":0,"volume":1453268,"delay":0,"floatShares":188000000,"shares":188000000,"eps":2.8103,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.12,"latestTime":"04-30 15:00:00","open":73,"high":73,"low":71.9,"amount":106000000,"amplitude":0.0151,"askPrice":72.66,"askSize":303,"bidPrice":72.63,"bidSize":5,"shortable":0,"etf":0,"ttmEps":2.8103,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"adjPreClose":72.78,"symbolType":"stock_kcb","openAndCloseTimeList":[[1714440600000,1714447800000],[1714453200000,1714460400000]],"highLimit":80.06,"lowLimit":65.5,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":187847422,"pbRate":3.67,"roa":"--","roe":"3.91%","epsLYR":2.59,"committee":-0.706294,"marketValue":13649000000,"floatMarketCap":13649000000,"peRate":25.85489,"changeRate":-0.0016,"turnoverRate":0.0077,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-05-06。","afterMarket":{"amount":0,"volume":0,"close":72.66,"buyVolume":0,"sellVolume":0,"time":1714462439505,"indexStatus":"已收盘 04-30 15:30:00","preClose":72.78}},"requestUrl":"/m/hq/s/688029/wiki","defaultTab":"wiki","newsList":[{"id":"2432300166","title":"南微医学获得发明专利授权：“一种压力泵控制方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2432300166","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2432300166?lang=zh_cn&edition=full","pubTime":"2024-05-01 02:40","pubTimestamp":1714502425,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示南微医学新获得一项发明专利授权，专利名为“一种压力泵控制方法”，专利申请号为CN201911375023.X，授权日为2024年4月30日。一种泵头，包括泵体、活塞、活塞杆及可膨胀的第一稳压管。今年以来南微医学新获得专利授权12个，较去年同期增加了33.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050100003042.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431870867","title":"【机构调研记录】财通基金调研温氏股份、南微医学等13只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2431870867","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431870867?lang=zh_cn&edition=full","pubTime":"2024-04-30 08:04","pubTimestamp":1714435491,"startTime":"0","endTime":"0","summary":"3）长江电力 个股亮点：公司为中特估概念股。4）恒玄科技 个股亮点：公司是智能音频SoC芯片龙头企业。8）智洋创新 个股亮点：公司有风电场智能巡视系统。旗下最近一年表现最佳的公募基金产品为财通福佑定开混合发起，最新单位净值为1.55，近一年增长62.35%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000014280.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431877091","title":"【机构调研记录】红土创新基金调研南微医学、传音控股等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2431877091","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431877091?lang=zh_cn&edition=full","pubTime":"2024-04-30 08:04","pubTimestamp":1714435480,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月29日披露的机构调研信息，红土创新基金近期对4家上市公司进行了调研，相关名单如下：1）南微医学 南微医学2024年一季报显示，公司主营收入6.2亿元，同比上升12.72%；归母净利润1.43亿元，同比上升41.36%；扣非净利润1.41亿元，同比上升42.21%；负债率13.57%，投资收益280.37万元，财务费用-299.14万元，毛利率68.31%。旗下最近一年表现最佳的公募基金产品为红土创新增强收益债券A，最新单位净值为1.39，近一年增长5.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000014271.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431487798","title":"【机构调研记录】国新国证基金调研南微医学、云涌科技等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2431487798","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431487798?lang=zh_cn&edition=full","pubTime":"2024-04-30 08:03","pubTimestamp":1714435392,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月29日披露的机构调研信息，国新国证基金近期对3家上市公司进行了调研，相关名单如下：1）南微医学 南微医学2024年一季报显示，公司主营收入6.2亿元，同比上升12.72%；归母净利润1.43亿元，同比上升41.36%；扣非净利润1.41亿元，同比上升42.21%；负债率13.57%，投资收益280.37万元，财务费用-299.14万元，毛利率68.31%。旗下最近一年表现最佳的公募基金产品为国新国证雄安建设发展三年定开债，最新单位净值为1.09，近一年增长4.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043008055687c14ced&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043008055687c14ced&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431877389","title":"【机构调研记录】先锋基金调研温氏股份、南微医学等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2431877389","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431877389?lang=zh_cn&edition=full","pubTime":"2024-04-30 08:02","pubTimestamp":1714435328,"startTime":"0","endTime":"0","summary":"旗下最近一年表现最佳的公募基金产品为先锋精一混合A，最新单位净值为0.79，近一年增长-5.32%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000014134.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431877311","title":"【机构调研记录】中庚基金调研华明装备、南微医学等6只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2431877311","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431877311?lang=zh_cn&edition=full","pubTime":"2024-04-30 08:01","pubTimestamp":1714435302,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月29日披露的机构调研信息，中庚基金近期对6家上市公司进行了调研，相关名单如下：1）华明装备 个股亮点：公司是国内最大以型钢为加工对象专用数控成套加工设备制造商；公司研制开发的国内首台双机器人，且是自动化数控企业；公司是目前国内唯一掌握特高压分接开关技术的企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024043000014123.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431872985","title":"【私募调研记录】汐泰投资调研南微医学、海油发展等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2431872985","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431872985?lang=zh_cn&edition=full","pubTime":"2024-04-30 08:00","pubTimestamp":1714435249,"startTime":"0","endTime":"0","summary":"根据市场公开信息及4月29日披露的机构调研信息，知名私募汐泰投资近期对3家上市公司进行了调研，相关名单如下：1）南微医学 南微医学2024年一季报显示，公司主营收入6.2亿元，同比上升12.72%；归母净利润1.43亿元，同比上升41.36%；扣非净利润1.41亿元，同比上升42.21%；负债率13.57%，投资收益280.37万元，财务费用-299.14万元，毛利率68.31%。2）海油发展 个股亮点：公司涉及天然气批发及零售商分销、液化天然气运输业务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300801208b63e91a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404300801208b63e91a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431349668","title":"南微医学：公司预计，欧盟相关调查及国内集采不会对今年业绩造成较大影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2431349668","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431349668?lang=zh_cn&edition=full","pubTime":"2024-04-29 19:03","pubTimestamp":1714388582,"startTime":"0","endTime":"0","summary":"南微医学董秘：尊敬的投资者您好，公司在美欧日三个区域的销售收入占总营收约为40%。南微医学董秘：尊敬的投资者您好，3+n中选结果公布后目前正处在医院勾标报量阶段，具体市场份额尚不可知。实在是让人无语南微医学董秘：尊敬的投资者您好，公司部分股东减持系出于自身资金需求，与公司经营情况无关。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042919053987bef58b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042919053987bef58b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431009412","title":"南微医学04月29日遭主力抛售2476万元 环比增加120.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431009412","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431009412?lang=zh_cn&edition=full","pubTime":"2024-04-29 15:19","pubTimestamp":1714375159,"startTime":"0","endTime":"0","summary":"04月29日, 南微医学股价涨2.64%，报收72.78元，成交金额2.15亿元，换手率1.57%，振幅3.61%，量比1.14。南微医学今日主力资金净流出2476万元，连续3日净流出，上一交易日主力净流出1123万元，今日环比增加120.48%。该股近5个交易日上涨11.45%，主力资金累计净流出2481万元；近20日主力资金累计净流出1751万元，其中净流出天数为7日。净流出前三个股分别为南微医学、鱼跃医疗、健帆生物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291537018b60cff4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291537018b60cff4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430405261","title":"南微医学(688029)：利润超预期 规模扩张转为价值增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2430405261","media":"国泰君安证券股...","top":-1,"share":"https://www.laohu8.com/m/news/2430405261?lang=zh_cn&edition=full","pubTime":"2024-04-28 21:06","pubTimestamp":1714309603,"startTime":"0","endTime":"0","summary":"本报告导读：2024Q1 利润超预期，境外发展态势迅猛，通过提升产品毛利率及缩减管理/研发费用，规模扩张正逐步转为价值增长，维持增持评级。2023 及2024Q1 利润增速显著快于收入增速，2023 毛利率为64.5%，其中止血夹、活检、扩张等主要品类毛利率均有提升，通过引入自动化工艺、优化采购成本等，实现降本增效。2024Q1 毛利率持续同比提升5.4pct 达68.31%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042821065187baed01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042821065187baed01&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430076702","title":"南微医学(688029)：2023年业绩符合预期 海外业务加速成长","url":"https://stock-news.laohu8.com/highlight/detail?id=2430076702","media":"中金公司","top":-1,"share":"https://www.laohu8.com/m/news/2430076702?lang=zh_cn&edition=full","pubTime":"2024-04-27 13:34","pubTimestamp":1714196055,"startTime":"0","endTime":"0","summary":"2023 年业绩符合我们预期公司公布2023 年及1Q24 业绩：2023 年收入24.1 亿元，同比增长21.8%；归母净利润4.9 亿元，同比增长47.0%。公司业绩符合我们预期。1Q24 止血夹收入2.3 亿元，国内收入同比下滑至1.4 亿元，主要系集采落地前经销商库存调整。海外业务加速成长。盈利预测与估值由于对海外直销占比提升拉动毛利率的看好，我们上调2024 年EPS 预测8.1%至3.3 元，首次引入2025 年EPS 预测4.1 元。风险行业政策对价格影响，地区政策对海外业务影响，市场竞争恶化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404271334188b59a364&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404271334188b59a364&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430775721","title":"南微医学(688029)：国内稳步增长 海外高增持续","url":"https://stock-news.laohu8.com/highlight/detail?id=2430775721","media":"浙商证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2430775721?lang=zh_cn&edition=full","pubTime":"2024-04-27 09:41","pubTimestamp":1714182083,"startTime":"0","endTime":"0","summary":"净利率：2023 年公司销售净利率20.51%，同比增加3.71pct。我们预计，公司营收已逐步恢复至稳定增长态势，公司净利率有望维持稳定。我们认为，随着公司海外直销团队收入规模的快速提升，直销占比的稳步提升，以及可视化等新业务规模效应逐步显现，2024-2026 年公司毛利率、净利率仍有小幅提升趋势。随着国内手术量快速恢复，以及公司海外营销网络的逐步优化和可视化等新业务的持续放量并贡献第二增长动力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042709412487b59b09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042709412487b59b09&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430228238","title":"南微医学(688029)：23年业绩符合预期 公司持续加深海外渠道建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2430228238","media":"广发证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2430228238?lang=zh_cn&edition=full","pubTime":"2024-04-26 17:22","pubTimestamp":1714123338,"startTime":"0","endTime":"0","summary":"核心观点：公司23 年业绩符合预期，降本增效取得实质性效益增长。根据公司23年年报，公司实现营业总收入24.11 亿元；归母净利润 4.86 亿元；毛利率64.5%，系公司进行降本增效。23 年业绩表现出色主要系止血及闭合类，ERCP 类及EMR/ESD 类等产品销售量增长所致。根据wind ， 公司24Q1 实现收入6.2 亿元，归母净利润1.43 亿元，净利润增速高主要系公司销售收入增长12.72%。公司加深海外渠道建设。公司整体费率优化。销售不及预期、研发进展不及预期、政策影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261722328b568cdd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261722328b568cdd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430228295","title":"南微医学(688029)3月31日股东户数1.04万户，较上期增加29.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430228295","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430228295?lang=zh_cn&edition=full","pubTime":"2024-04-26 17:12","pubTimestamp":1714122765,"startTime":"0","endTime":"0","summary":"证券之星消息，近日南微医学披露，截至2024年3月31日公司股东户数为1.04万户，较12月31日增加2346.0户，增幅为29.3%。在医疗器械行业个股中，南微医学股东户数低于行业平均水平，截至3月31日，医疗器械行业平均股东户数为2.11万户。从股价来看，2023年12月31日至2024年3月31日，南微医学区间跌幅为31.12%，在此期间股东户数增加2346.0户，增幅为29.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042617202887b2ee44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042617202887b2ee44&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430242273","title":"东吴证券：给予南微医学买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2430242273","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430242273?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:39","pubTimestamp":1714120779,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对南微医学进行研究并发布了研究报告《2023年年报及2024年一季报点评：业绩符合预期，海外市场逐步打开》，本报告对南微医学给出买入评级，当前股价为70.91元。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级5家，增持评级2家；过去90天内机构目标均价为84.75。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600036791.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430242098","title":"东吴证券给予南微医学买入评级，2023年年报及2024年一季报点评：业绩符合预期，海外市场逐步打开","url":"https://stock-news.laohu8.com/highlight/detail?id=2430242098","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430242098?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:26","pubTimestamp":1714119995,"startTime":"0","endTime":"0","summary":"东吴证券04月26日发布研报称，给予南微医学（688029.SH，最新价：70.91元）买入评级。评级理由主要包括：1）2023年国内各项业务稳健增长；2）海外市场逐步打开，启动泰国生产基地建设；3）降本增效显著，净利率持续提升。风险提示：国内集采扩面导致国内业绩下滑风险，诊疗量恢复不及预期风险，市场竞争加剧风险，海外市场竞争风险。AI点评：南微医学近一个月获得1份券商研报关注，买入1家。文章来源：每日经济新闻原标题：东吴证券给予南微医学买入评级，2023年年报及2024年一季报点评：业绩符合预期，海外市场逐步打开","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042616392787b2bb01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042616392787b2bb01&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430924679","title":"南微医学2023年营收24.11亿净利4.86亿 董事长隆晓辉薪酬487万","url":"https://stock-news.laohu8.com/highlight/detail?id=2430924679","media":"挖贝网","top":-1,"share":"https://www.laohu8.com/m/news/2430924679?lang=zh_cn&edition=full","pubTime":"2024-04-26 15:50","pubTimestamp":1714117848,"startTime":"0","endTime":"0","summary":"挖贝网4月26日，南微医学 近日发布2023年度报告，报告期内公司实现营业收入2,411,468,385.36元，同比增长21.78%；归属于上市公司股东的净利润485,924,270.19元，同比增长46.99%。报告期内经营活动产生的现金流量净额为545,574,760.97元，截至2023年末归属于上市公司股东的净资产3,611,919,944.60元。公告显示，报告期内董事、监事、高级管理人员报酬合计4,094.43万元。公司2023年度拟以实施权益分派股权登记日登记的总股本扣减公司回购专用证券账户中股份为基数分配利润。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042616005187b2902b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042616005187b2902b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430216218","title":"南微医学(688029)：海外收入快速增长 盈利持续改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2430216218","media":"华泰证券","top":-1,"share":"https://www.laohu8.com/m/news/2430216218?lang=zh_cn&edition=full","pubTime":"2024-04-26 13:34","pubTimestamp":1714109667,"startTime":"0","endTime":"0","summary":"1Q24 净利润增速亮眼，盈利能力持续改善公司23 年营业收入/归母净利润/扣非归母净利润24.11/4.86/4.63 亿元，同比+21.8%/+47.0%/+54.7%，符合业绩快报。我们认为高利润增速主因相对低基数影响，以及公司降本增效成果逐步体现、盈利能力持续改善。考虑到公司降本增效下盈利能力持续改善，我们给予公司24 年29x PE 估值，目标价95.36 元，维持“买入”评级。23 年国内收入同比稳定增长，海外收入快速增长1）国内：23 年收入13.5 亿元，同比+18.2%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042613343187b206dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042613343187b206dc&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430258967","title":"图解南微医学一季报：第一季度单季净利润同比增41.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430258967","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430258967?lang=zh_cn&edition=full","pubTime":"2024-04-26 02:03","pubTimestamp":1714068207,"startTime":"0","endTime":"0","summary":"证券之星消息，南微医学2024年一季报显示，公司主营收入6.2亿元，同比上升12.72%；归母净利润1.43亿元，同比上升41.36%；扣非净利润1.41亿元，同比上升42.21%；负债率13.57%，投资收益280.37万元，财务费用-299.14万元，毛利率68.31%。财报数据概要请见下图:以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042602155287b037e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042602155287b037e1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430343472","title":"图解南微医学年报：第四季度单季净利润同比减4.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430343472","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430343472?lang=zh_cn&edition=full","pubTime":"2024-04-26 00:43","pubTimestamp":1714063405,"startTime":"0","endTime":"0","summary":"证券之星消息，南微医学2023年年报显示，公司主营收入24.11亿元，同比上升21.78%；归母净利润4.86亿元，同比上升46.99%；扣非净利润4.63亿元，同比上升54.67%；其中2023年第四季度，公司单季度主营收入6.66亿元，同比上升42.33%；单季度归母净利润9939.8万元，同比下降4.09%；单季度扣非净利润8564.32万元，同比上升3.16%；负债率16.45%，投资收益2782.48万元，财务费用-7783.24万元，毛利率64.5%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042601012687b00e07&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042601012687b00e07&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2019-07-22","address":"江苏省南京市浦口区高新开发区高科三路10号","stockEarnings":[{"period":"1week","weight":0.0984},{"period":"1month","weight":0.0897},{"period":"3month","weight":-0.0133},{"period":"6month","weight":-0.1699},{"period":"1year","weight":-0.1817},{"period":"ytd","weight":-0.2494}],"companyName":"南微医学科技股份有限公司","boardCode":"AI0035","perCapita":"18144股","boardName":"专用设备制造业","registeredCapital":"18784万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":" 南微医学科技股份有限公司的主营业务为微创医疗器械的研发、制造和销售。公司主要产品包括内镜诊疗器械、微波消融设备及耗材、一次性内镜。公司内镜诊疗器械主要包括活检类、止血和闭合类、EMR/ESD 类、扩张类、ERCP 类、EUS/EBUS类等六大类60多种上百个规格系列产品，微波消融主要包括微波消融仪和微波消融针系列产品。公司是我国内镜诊疗器械的主要制造商之一，是国内内镜诊疗器械、耗材细分领域中起步较早、创新能力强、产品线丰富、规模优势明显、迈向国际化的行业龙头企业。","serverTime":1714626939087,"listedPrice":52.45,"stockholders":"10353人(较上一季度增加29.30%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"南微医学(688029)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供南微医学(688029)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"南微医学,688029,南微医学股票,南微医学股票老虎,南微医学股票老虎国际,南微医学行情,南微医学股票行情,南微医学股价,南微医学股市,南微医学股票价格,南微医学股票交易,南微医学股票购买,南微医学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"南微医学(688029)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供南微医学(688029)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}